Ultragenyx Pharmaceutical (RARE) Competitors $44.92 +1.98 (+4.62%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RARE vs. SMMT, GMAB, VTRS, ITCI, MRNA, RDY, CTLT, SRPT, PCVX, and QGENShould you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Ultragenyx Pharmaceutical vs. Summit Therapeutics Genmab A/S Viatris Intra-Cellular Therapies Moderna Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Vaxcyte Qiagen Summit Therapeutics (NASDAQ:SMMT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership, community ranking and media sentiment. Do analysts recommend SMMT or RARE? Summit Therapeutics currently has a consensus price target of $33.57, indicating a potential upside of 42.75%. Ultragenyx Pharmaceutical has a consensus price target of $92.43, indicating a potential upside of 111.82%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Does the media favor SMMT or RARE? In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than Summit Therapeutics. MarketBeat recorded 20 mentions for Ultragenyx Pharmaceutical and 12 mentions for Summit Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.81 beat Summit Therapeutics' score of 0.69 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in SMMT or RARE? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer SMMT or RARE? Ultragenyx Pharmaceutical received 530 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 77.42% of users gave Ultragenyx Pharmaceutical an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30358.38% Underperform Votes21641.62% Ultragenyx PharmaceuticalOutperform Votes83377.42% Underperform Votes24322.58% Which has more risk and volatility, SMMT or RARE? Summit Therapeutics has a beta of -0.87, meaning that its share price is 187% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Which has stronger valuation and earnings, SMMT or RARE? Ultragenyx Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K24,775.16-$614.93M-$0.28-83.99Ultragenyx Pharmaceutical$434.25M9.28-$606.64M-$6.47-6.74 Is SMMT or RARE more profitable? Summit Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -106.93%. Summit Therapeutics' return on equity of -85.42% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Ultragenyx Pharmaceutical -106.93%-187.12%-37.55% SummaryUltragenyx Pharmaceutical beats Summit Therapeutics on 13 of the 18 factors compared between the two stocks. Get Ultragenyx Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RARE vs. The Competition Export to ExcelMetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.03B$6.54B$5.42B$9.22BDividend YieldN/A2.94%5.36%3.97%P/E Ratio-6.749.5886.9717.48Price / Sales9.28331.271,248.8779.08Price / CashN/A66.9244.6537.70Price / Book13.035.094.984.69Net Income-$606.64M$154.66M$117.90M$224.69M7 Day Performance6.82%1.41%1.85%1.24%1 Month Performance-0.54%0.43%3.28%4.00%1 Year Performance-1.90%4.97%25.77%21.94% Ultragenyx Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAREUltragenyx Pharmaceutical4.6726 of 5 stars$44.92+4.6%$92.43+105.7%-3.8%$4.15B$434.25M-6.951,276Analyst ForecastAnalyst RevisionGap DownSMMTSummit Therapeutics2.8425 of 5 stars$19.03+4.6%$33.57+76.4%+523.9%$14.03B$700,000.00-67.96110Analyst ForecastGap DownGMABGenmab A/S4.3807 of 5 stars$20.80-2.0%$45.20+117.3%-26.9%$13.76B$2.39B20.192,204Analyst ForecastAnalyst RevisionNews CoverageVTRSViatris2.2071 of 5 stars$11.30-0.4%$13.67+20.9%-4.3%$13.49B$15.43B-15.2738,000ITCIIntra-Cellular Therapies3.88 of 5 stars$126.200.0%$100.31-20.5%+88.9%$13.38B$612.78M-145.06560Analyst ForecastAnalyst RevisionHigh Trading VolumeMRNAModerna4.6822 of 5 stars$34.06+0.9%$75.58+121.9%-61.4%$13.11B$6.85B-5.855,600Options VolumeRDYDr. Reddy's Laboratories2.2124 of 5 stars$14.91+0.5%$17.00+14.0%+11.7%$12.44B$3.35B23.8227,048Earnings ReportUpcoming EarningsNews CoverageCTLTCatalent1.2292 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.38B-28.0916,900Analyst ForecastNews CoverageSRPTSarepta Therapeutics4.9704 of 5 stars$118.00+0.8%$178.71+51.5%-4.1%$11.27B$1.24B94.401,314Analyst RevisionPCVXVaxcyte1.8978 of 5 stars$85.30-2.9%$145.71+70.8%+37.0%$10.63BN/A-18.54160Insider TradeAnalyst RevisionNews CoverageQGENQiagen3.9964 of 5 stars$46.00+0.2%$51.50+12.0%+2.2%$10.50B$1.97B117.945,967 Related Companies and Tools Related Companies Summit Therapeutics Alternatives Genmab A/S Alternatives Viatris Alternatives Intra-Cellular Therapies Alternatives Moderna Alternatives Dr. Reddy's Laboratories Alternatives Catalent Alternatives Sarepta Therapeutics Alternatives Vaxcyte Alternatives Qiagen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RARE) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second ter...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
